Drug Profile
Hepatitis B immune globulin - ADMA Biologics
Alternative Names: HBVIg - Biotetst Pharmaceuticals; HBVIg - Nabi Biopharmaceuticals; HEBIG; Hepatitis B immune globulin-human - Biotest Pharmaceuticals; Human hepatitis B immunoglobulin - Biotest Pharmaceuticals; Nabi-HBLatest Information Update: 10 Jul 2019
Price :
$50
*
At a glance
- Originator Nabi Biopharmaceuticals
- Developer ADMA Biologics
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 02 Jul 2019 The US FDA completes the license transfer for Nabi-HB® to ADMA Biologics
- 01 Aug 2018 Biotest Pharmaceuticals has been acquired by Grifols Shared Services North America
- 07 Jun 2017 ADMA biologics acquires Hepatitis B immune globulin, immunoglobulin G from Biotest Pharmaceuticals Corporation’s Therapy Business Unit